The Sensex will hover between 56777 and 55666 in the new week

(Gujarat News Correspondent) MUMBAI: With the second wave of Coro's transition being lethal, the number of positive cases is on the rise in some states, including Maharashtra, with the sudden outbreak of cases in Kerala amid the third wave of scandals. Is. With the progress of the monsoon slowing down, reports of drought in some states, including Gujarat, and concerns over inflation are still lingering, with the Sensex and Nifty setting new records in the Indian stock market amid negative factors of geopolitical tension over Afghanistan. In the wake of sustained sell-offs in foreign portfolio investors (FPIs) stocks, local funds, local institutional investors' net purchases in stocks have given the market a fresh start in the last few days. In which now the U.S. With no indication of a Federal Reserve retreat in stimulus on Friday and a positive factor in the central government's Rs 5 lakh crore asset monetization scheme and various projects in Uttar Pradesh, Gujarat preparing for the elections, the exercise to speed up the development market Sentiment is being seen as an attempt to keep it bullish. In the coming days, small, mid-cap stocks will see a very selective rally in small, mid-cap stocks, with signs that funds have shifted in two weeks, large investors switched portfolios and sold to a lot of cash stocks. So it will be necessary to be very careful in new investments.

100% peak margin now effective from September 1, preferred stocks rise, weaker stocks likely to break low volume

SEBI, in a phased implementation of regulatory changes in May 2021 to collect and report client's peak margins in the cash and derivatives segment, is now in the final stages. The number of intra-day trading classes is likely to decline with the possibility of declining liquidity, and low volume stocks are likely to fall in the event of a decline in trading volume in many stocks. But with traders' intra-day hurricane-lows, there will also be stocks that could see a tumultuous rally. So that the implementation of the rules of peak margin is not one-sided, but a big rally in stocks can also be seen. Of course, in the event of a decline in trading volume, there will be stocks that will be difficult to sell. Next week, the infrastructure production figures for July 2021 will be released on 31, August 2021, and India's GPD growth figures for April to June 2021 will also be released on 31, August 2021. On the other hand, the manufacturing PMI for August 2018 and the market services PMI for September 1, 2021 will be released. The market will also keep an eye on the August sales figures for automobile companies from September 1, 2021. Along with this, Indian markets along with global markets will keep an eye on the progress of the special monsoon, the transition to Koro and the situation in Afghanistan on the international front. Given this, the Sensex is likely to fluctuate between 7 and 8 and the Nifty spot between 16 and 17 next week.

Dark Horse: Bliss GVS Pharma Ltd.

BSE (20918), NSE (BLISSGVS) Listed, Rs. 1 Paid-up, EU GMP, WHO GMP, OHSAS-18001: 2007, ISO 14001: 2004 Certified Bliss GVS Pharma Ltd., a company with a track record of developing, manufacturing and selling high quality pharmaceutical formulations for the global market, with a bonus equity of 4.5 per cent of the total equity through two bonus issues. The company is one of the leading companies in the world with the largest portfolio in this segment in suppositories and pessaries dosage forms. Over the past decade, the company has been gaining exposure in other dosage forms and therapeutic segments, offering its expanded products in more than 20 countries. The company is going to grow at a rapid rate with a significant expansion in R&D, manufacturing and marketing capabilities.

Manufacturing facilities:

The company has five manufacturing units in Maharashtra. In which (1) capacity of 20 lakh units of WHO-GMP approved suppositories and pessaries in Palghar annually, 20 million tablets and 3 million units of dry syrup capacity (3) The third unit in Palghar alone has an annual capacity of 3 lakh units of WHO-GMP approved suppositories and pessaries and a unit with a capacity of 212 lakh units of cachetes. Has an annual capacity. (5) The fifth unit at Ambernath-Thane in Maharashtra has WHO-GMP approved ointments, creams and gels with a capacity of 3 lakh tubes per annum. (2) The company is setting up its sixth manufacturing unit at Palghar.

The company is a leader in this segment in most African markets in malaria resistant products. The company's brands include artemisinin-based combination formulations in tablets, suspensions, suppositories and injections in various dosage forms. The company owns the Lonart flagship brand for the combination of Artemether and Lumifentrine. Over the past decade, the company has expanded its product portfolio across various therapeutic segments. In the dermatology segment, the company Funbect Brant is now a leader in the anti-fungal segment. The company only does formulation development and contract manufacturing for its leading domestic and international demand for global leading companies. The company also does contract manufacturing of pesaris for global leading entrepreneurs. The company is the only manufacturer of EU-GMPP certified suppositories and pizzerias in India.

The company's pharma products include capsules, creams-gels-ointment, dry powder for injection, dry powder for oral suspension, efficacious tablets, eye-ear drops, injections, liquid preparations, lotions, lotions, lotions, lotions, , Soft gelatin capsules, suppositories manufacturing, suspensions, syrups, tablets, topical preparations, shampoo, soap and other healthcare products.

Share holding parton:

Promoters hold 4.7 per cent, Foreign Portfolio Investors (FPIs) hold 21.5 per cent, Aspire Emerging Fund has 2.4 per cent, Fidelity Puritan Trust has 2.50 per cent, Arian Investment Limited has 2.50 per cent, Has 7.5 percent. Life Insurance Corporation of India owns 7.5 per cent. Arjun Gautam Ashara has 7.5 per cent and Gautam Rasiklal Ashara has 7.5 per cent. Apart from this, Gulbarga Trading and Investment Pvt. Has 7.5 percent. While individual shareholders up to Rs 5 lakh have 16.12 per cent.

Bonus History:

3: 4 bonus in the year 2006, 3: 3 share bonus issue in the year 2006

Dividends:

20% in 2014, 30% in 2014, 30% in 2014, 100% in 2014, 100% in 2014, 20% in 2020, 20% in 2021

Book value:

Rs.5.5 as on March 2018, Rs.2.5 as on March 2020, Rs.30.5 as on March 2021, Rs.21.05 as expected on March 303

Financial Outcome:

(1) Full year April 2020 to March 2021:

On a consolidated basis, net income fell to Rs 2.50 crore from Rs 2.50 crore, net profit fell from Rs 4.5 crore to Rs 4.5 crore, earnings per share fell from Rs 3.5 to Rs 4.5 crore. Achieved.

(2) First Quarter April 2021 to June 2021:

Net profit rose 2.6 per cent to Rs 19.15 crore from Rs 12.5 crore, net profit rose Rs 4.5 crore to Rs 5.15 crore from Rs 12.5 crore Has increased to Rs.5.5.

(2) Expected full year April 2021 to March 303:

Earnings per share - EPS of Rs.

(2) Valuation: BBB:

Even if we give the company a P / E of 12 against the average P / E of 8 in the pharmaceuticals industry, the valuation is triple BBB so that the share can go up to Rs.

Thus (1) holding 2.7 per cent of promoters, holding 31.5 per cent holding of foreign portfolio investors, (2) holding, developing, manufacturing and selling tracking of high quality pharmaceutical formulations at affordable prices for global markets. One of the world's leading companies with the largest portfolio in this segment in the form of (1) first quarter from April 2021 to June 2021 with a net profit growth of 4.5 per cent to Rs 2.18 crore and earnings per share of Rs 4.5 crore (2) expected completion. From April 2021 to March 203, the expected earnings per share was Rs. 10.8 and the expected book value was Rs. 21.05. EA is available.

Manoj Shah: Research Analyst (SEBI REG. NO. INH000000107)

The author is a SEBI registered research analyst: Disclosure cum (readers should take special note) Warning: (1) The author has no investment in the shares of the above companies. (2) Our resources for researchers may be of direct or indirect interest to brokers, promoter views, personal research analysts, portfolio management or their team. (3) Maintaining a 30% stop loss from the Reachers price, in particular, is advice and warning. (2) Valuation H, B, BB, BBB, Top Gainers These are all possibilities, so don't invest temptingly. (2) Generally, out of every 10 scrips, 4 scrips are true and 4-5 scrips are false. This type of research is excellent. (2) Feedback E-mail: All the above points also apply to the answers given in arjuneyems@gmail.com. (2) The reader class, the investor class to take their own personal decisions at personal risk. The writer, editor and anyone of Gujarat Samachar will not be responsible for your loss. So invest by recognizing the risk of the stock market.